Artisan Partners
NRIX icon

Artisan Partners’s Nurix Therapeutics NRIX Stock Holding History

Artisan Partners’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-580,749
Closed -$6.61M – 363
2025
Q2 		$6.61M Sell
580,749
-57,860
-9% -$625K 0.01% 319
2025
Q1 		$7.59M Buy
+638,609
New +$10.7M 0.01% 313

Other funds holding NRIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Artisan Partners's NRIX Position: Q3 2025 in Review

Artisan Partners sold out of Nurix Therapeutics (NRIX) in Q3 2025, closing a stake of 580,749 shares — an estimated $6.61M sold.

Artisan Partners first reported a position in NRIX in Q1 2025 and held it in 2 quarters. The position peaked at $7.59M in Q1 2025. 173 funds tracked by Wall St. Rank hold NRIX as of Q3 2025.

  • Artisan Partners reported no remaining Nurix Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Artisan Partners sold 580,749 Nurix Therapeutics shares in Q3 2025, an estimated $6.61M.
  • Artisan Partners first reported a position in Nurix Therapeutics in Q1 2025 and held it in 2 quarters.
  • Artisan Partners's Nurix Therapeutics position peaked at $7.59M in Q1 2025.
  • 173 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2025.

Based on Artisan Partners's 13F filing for Q3 2025, filed 12 Nov 2025.